Thomas Ragole, MD
Neurology · Aurora, CONPI 1437577897
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $28,640 of the $30,960 with a category attached, or 92.5%. AstraZeneca accounts for 76.3% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $15,657 and has fallen 76.3% since, to $3,704 in 2025.
Across 33 payments — averaging $938.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$24K
- UCB, Inc.$7K
- Cadwell Industries, Inc$14
- CSL Behring$11
Across 35 payments — averaging $23,139 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Argenx US, Inc.$385K
- AstraZeneca$267K
- UCB SA$80K
- Sanofi$54K
- Takeda Pharmaceuticals U.S.A., Inc.$24K
What the payments were for
- Consulting fees$28,64093%
- Speaking & faculty fees$2001%
- Travel & lodging$1,6635%
- Food & beverage$4451%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $23,620 |
| UCB, Inc. | 6 | $7,315 |
| Cadwell Industries, Inc | 1 | $14 |
| CSL Behring | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,960 in reported general payments places this provider in the 85th percentile of 334 neurology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 43 | $493,708 |
| Radicava OrsEdaravone | 11 | $154,326 |
| Mycophenolate Mofetil | 19 | $9,740 |
| Pyridostigmine Bromide | 15 | $2,328 |
| Azathioprine | 12 | $921 |
| Pregabalin | 30 | $751 |
| Prednisone | 75 | $698 |
| Carbamazepine ErCarbamazepine | 12 | $537 |
| Dexamethasone | 11 | $362 |
| Baclofen | 15 | $351 |
| Methylprednisolone Sodium SuccMethylprednisolone Sod Succ | 14 | $319 |
| Sodium Chloride0.9 % Sodium Chloride | 13 | $161 |
| Promethazine Hcl | 13 | $97 |
| Topiramate | 14 | $95 |
| Ketorolac Tromethamine | 15 | $77 |
Paid to pharmacies, not to this prescriber.
Other neurology in Aurora
- Jeffrey BennettAurora$605K
- Enrique AlvarezAurora$407K
- Anna ShahAurora$157K
- Timothy VollmerAurora$136K
- Simon OhAurora$112K
- Amanda PiquetAurora$106K
- Brent MorelAurora$79K
- Drew KernAurora$68K
- Ondrea TimmermannAurora$33K
- Maria NagelAurora$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.